| Original language | English (US) |
|---|---|
| Article number | 17 |
| Journal | Blood cancer journal |
| Volume | 11 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2021 |
ASJC Scopus subject areas
- Hematology
- Oncology
MD Anderson CCSG core facilities
- Biostatistics Resource Group
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood cancer journal, Vol. 11, No. 2, 17, 02.2021.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up
AU - Manasanch, Elisabet E.
AU - Kunacheewa, Chutima
AU - Claussen, Catherine M.
AU - Lee, Hans C.
AU - Thomas, Sheeba K.
AU - Gunther, Jill
AU - Pinnix, Chelsea C.
AU - Dabaja, Bouthaina S.
AU - Amini, Behrang
AU - Alexanian, Raymond
AU - Orlowski, Robert Z.
AU - Dong, Wenli
AU - Feng, Lei
AU - Weber, Donna M.
N1 - Funding Information: E.M. has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, Merck; consultant fees from Takeda, Celgene, Sanofi, Janssen and Adaptive Biotechnologies. C.K. reports no conflicts of interest. C.M.C. reports no conflicts of interest. H.L. has received consulting fees from Adaptive Biotechnologies, Celgene, Pimera, and Takeda, and research support from Amgen, Daiichi Sankyo, Janssen, and Takeda. S.T. reports no conflicts of interest. J.G. reports no conflicts of interest. C.C.P. reports no conflicts of interest. B.S.D. reports no conflicts of interest. B.A. reports no conflicts of interest. R.A. reports no conflicts of interest. R.O. has received consulting fees from Amgen, Bristol-Myers-Squibb, Celgene, GSK Biologicals, Ionis Pharmaceuticals, Janssen, Juno Therapeutics, Kite Pharma, Legend Biotech, Molecular Partners, Sanofi, Servier, and Takeda and research support from BioTheryX. W.D. reports no conflicts of interest. L.F. reports no conflicts of interest. D.W. reports no conflicts of interest. Funding Information: This work was also supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672), the Leukemia and Lymphoma Society Specialized Center of Research (LLS SCOR), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Multiple Myeloma Research Foundation, The Chapman Perelman Foundation, and the University of Texas MD Anderson Moon Shot Program. RZO, the Florence Maude Thomas Cancer Research Professor, would like to acknowledge support from the National Cancer Institute (R01s CA184464 and 194264, and U10 CA032102), the Leukemia & Lymphoma Society (SCOR-12206-17), the Brock Family Myeloma Research Fund, and the Jean Clarke High-Risk Myeloma Research Fund. We would like to thank participating patients and their families.
PY - 2021/2
Y1 - 2021/2
UR - http://www.scopus.com/inward/record.url?scp=85100810194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100810194&partnerID=8YFLogxK
U2 - 10.1038/s41408-021-00419-1
DO - 10.1038/s41408-021-00419-1
M3 - Letter
C2 - 33563896
AN - SCOPUS:85100810194
SN - 2044-5385
VL - 11
JO - Blood cancer journal
JF - Blood cancer journal
IS - 2
M1 - 17
ER -